BAXBaxter International
Is the price fair?
At the top of its own P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Expensive vs its own history: P/E 176.5 vs a 30.7 median over 30 quarters (+475% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What BAX's price assumes
Baxter International did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.90× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.66
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 0.78
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.66
- EV / EBIToperating margin −2.4%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 0.78
- Market capitalisation
- $10.3B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
The closest names by size in the same industry